Full Press Release Details
HELIUS MEDICAL TECHNOLOGIES ANNOUNCES ALLOWANCES OF 10 NEW
(Newtown, PA) - January 4, 2016 -
Helius Medical Technologies, Inc. (CSE: HSM; OTCQB:
HSDT) ("Helius", or the "Company"), a medical
technology company focused on the treatment of
neurological symptoms caused by disease or trauma,
announced today that ten (10) new patent
applications (seven US and three Chinese) have been allowed by the
US and Chinese Patent Offices in November and
December 2015 building on the already strong
patent portfolio of the company. The Company has a
further 33 patents (22 US and 11 international) pending on
its technology in the US and other markets around
| Co u ntry | St a tus | Title | Filed | Serial No. | Allo w ed |
| US | ALLOWED | Methods of Manufacturing Devices for the Neurorehabilitation of a Patient | 12/3/2014 | 14/559,123 | 12/21/2015 |
| US | ALLOWED | Devices for Delivering Non-Invasive Neuromodulation to a Patient | 12/3/2014 | 14/558,787 | 11/10/2015 |
| US | ALLOWED | A Non-Invasive Neurostimulation Device | 12/3/2014 | 29/510,741 | 12/9/2015 |
| US | ALLOWED | A Non-Invasive Neurostimulation Device | 12/3/2014 | 29/510,742 | 12/4/2015 |
| CN | ALLOWED | A Non-Invasive Neurostimulation Device | 6/3/2015 | 201530177804.4 | 11/2/2015 |
| US | ALLOWED | A Non-Invasive Neurostimulation Device | 12/3/2014 | 29/510,745 | 12/21/2015 |
| CN | ALLOWED | A Non-Invasive Neurostimulation Device | 6/3/2015 | 201530178171.9 | 11/2/2015 |
| US | ALLOWED | A Non-Invasive Neurostimulation Device | 12/3/2014 | 29/510,754 | 12/7/2015 |
| CN | ALLOWED | A Non-Invasive Neurostimulation Device | 6/3/2015 | 201530177398.1 | 11/2/2015 |
| US | ALLOWED | A Non-Invasive Neurostimulation Device | 12/3/2014 | 29/510,755 | 12/8/2015 |
"The patents listed above are design and utility patents that
will help defend against competitive intrusion into our market and I want to
thank Proskauer Rose for its expertise and passion in helping us create a robust
IP portfolio for the PoNS device," said CEO Phil Deschamps.
The PoNS device is a non-invasive means for delivering neurostimulation through the tongue. The PoNS therapy is currently being
studied in the United States and Canada for the treatment of balance disorder
for subjects with mild to moderate Traumatic Brain Injury ("mTBI"), and in
Canada for the treatment of gait and balance disorder for subjects with MS.
The PoNS device is believed to be the first non-invasive means
for delivering neurostimulation through the tongue. Researchers believe that use
of the tongue as a gateway to the brain may be one of the most natural,
non-invasive and direct ways to stimulate the brain. The tongue is anatomically
unique, being richly innervated by thousands of nerve fibers and interconnected
to the brainstem by two major cranial nerves.
About Helius Medical Technologies (HMT)
Helius Medical Technologies is a medical technology company
focused on neurological wellness. HMT seeks to develop, license and acquire
unique and non-invasive platform technologies that amplify the brain's ability
to heal itself. HMT intends to file for U.S. Food and Drug Administration
clearance for the PoNS device. For more information, please visit
www.heliusmedical.com. The contents of this website are not, and should
not be deemed to be, incorporated by reference herein.
Cautionary Disclaimer Statement:
The Canadian Securities Exchange has not reviewed and does
not accept responsibility for the adequacy or accuracy of the content of this
Forward-looking statements are often identified by terms such
as "will", "may", "should", "anticipate", "expects" and similar expressions. All
statements other than statements of historical fact, included in this release
are forward-looking statements that involve risks and uncertainties. There can
be no assurance that such statements will prove to be accurate and actual
results and future events could differ materially from those anticipated in such
statements. Important factors that could cause actual results to differ
materially from the Company's expectations include the failure to satisfy the
conditions of the Canadian Securities Exchange and other risks detailed from
time to time in the filings made by the Company with securities regulations.
The reader is cautioned that assumptions used in the
preparation of any forward-looking information may prove to be incorrect. Events
or circumstances may cause actual results to differ materially from those
predicted, as a result of numerous known and unknown risks, uncertainties, and
other factors, many of which are beyond the control of the Company. The reader
is cautioned not to place undue reliance on any forward-looking information.
Such information, although considered reasonable by management at the time of
preparation, may prove to be incorrect and actual results may differ materially
from those anticipated. Forward-looking statements contained in this news
release are expressly qualified by this cautionary statement. The
forward-looking statements contained in this news release are made as of the
date of this news release and the Company will update or revise publicly any of
the included forward-looking statements as expressly required by applicable law.